Searchable abstracts of presentations at key conferences in endocrinology

ea0049gp181 | Pituitary | ECE2017

Targeting either GH or IGF-I levels during somatostatin analogue treatment in patients with acromegaly: A randomized, investigator-initiated multicenter study

Dal Jakob , Klose Marianne , Heck Ansgar , Andersen Marianne , Kistorp Caroline , Nielsen Eigil Husted , Bollerslev Jens , Feldt-Rasmussen Ulla , Jorgensen Jens Otto Lunde

Context: Assessment of disease control in acromegaly depends on GH and IGF-I, but discordant values frequently occur. Further, the role of OGTT-suppressed GH (GHnadir) in somatostatin analogue (SA) treated patients is debated.Objective: To evaluate the effect of targeting either IGF-I or GH during SA treatment.Design: A randomized, investigator-initiated, multicentre trial.Patients and methods: 84 ...

ea0070aep1073 | Hot topics (including COVID-19) | ECE2020

A randomized-controlled trial of tesomet resulted in significant weight loss in hypopituitary patients with hypothalamic obesity

Huynh Kim , Klose Marianne , Krogsgaard Kim , Drejer Jorgen , Byberg Sarah , Madsbad Sten , Magkos Faidon , Aharaz Abdellatif , Edsberg Berit , Astrup Arne , Feldt-Rasmussen Ulla

Background and objective: Hypothalamic obesity is characterized by rapid and severe weight-gain with increased risk of cardiovascular and metabolic disorders. Currently, there are no approved or effective pharmacological treatments and conventional weight management remain largely ineffective in hypothalamic obesity. This trial investigated safety and efficacy of Tesomet (0.5 mg tesofensine and 50 mg metoprolol) in hypopituitary patients with hypothalamic obesity.<p class=...

ea0026p268 | Pituitary | ECE2011

Frequency of acute-onset symptoms and other features of craniopharyngioma presentation in children and adults

Nielsen E H , Jorgensen J O , Bjerre P , Andersen M , Andersen C , Feldt-Rasmussen U , Poulsgaard L , Kristensen L O , Astrup Jens , Lindholm Jorgen , Laurberg Peter

Introduction: Clinical symptoms in craniopharyngioma have been repeatedly described in the literature, but few studies have addressed the issue of acute-onset symptoms in children or adults. Refinements of diagnostic procedures and altered scanning routines over the last two decades may in theory have affected patterns of clinical presentation.Objective: To study the clinical phenotype of patients with newly diagnosed craniopharyngioma, with focus on var...

ea0022p617 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Epidemiology of craniopharyngioma in Denmark 1985–2004: a 2% increase in incidence rate per year

Husted Nielsen Eigil , Feldt-Rasmussen Ulla , Poulsgaard Lars , Ostergaard Kristensen Lars , Astrup Jens , Otto Jorgensen Jens , Bjerre Per , Andersen Marianne , Andersen Claus , Jorgensen Jesper , Lindholm Jorgen , Laurberg Peter

Background: Craniopharyngioma may be associated with severe morbidity. Few data exist on incidence rate (IR) and possible changes with time. The epidemiology of craniopharyngioma in Denmark has never been evaluated in detail.Objectives: To review the literature on craniopharyngioma incidence and to study the epidemiology of craniopharyngioma in Denmark during a recent 20-year period.Material and methods: Publications including data...

ea0014p67 | (1) | ECE2007

Intravenous constant ghrelin infusion in healthy young men: sustained cardiovascular effects of supraphysiological ghrelin levels

Vestergaard Esben Thyssen , Andersen Niels Holmark , Hansen Troels Krarup , Rasmussen Lars Melholt , Moller Niels , Sorensen Keld , Sloth Erik , Christiansen Jens Sandahl , Jorgensen Jens Otto Lunde

Objective: The short-term cardiovascular effects of continuous ghrelin infusion in healthy humans remain to be studied.Methods: Fifteen healthy, young and normal-weight men volunteered to participate in a randomized double-blind, placebo-controlled cross-over study. The local ethics committee approved the study. We used a constant infusion of human ghrelin at a rate of 5 pmol/kg body weight per minute for 180 minutes and measured peak left ventricular my...

ea0056gp8 | Acromegaly | ECE2018

ACRONIS, a European observational study in patients with uncontrolled acromegaly who are being treated with long acting pasireotide: first interim analysis

Schofl Christof , Colao Annamaria , Neggers SJCMM , Feldt-Rasmussen Ulla , Moreno Eva Maria Venegas , Enderle Gesine , Mesenska Daniela , Andry Philippe , Tabarin Antoine

Acromegaly is a morbid condition mainly caused by overproduction of growth-hormone (GH) from a pituitary adenoma leading to excessive growth. Normalisation of insulin-like growth factor-1 (IGF1) is an important goal for the treatment of acromegaly. The second-generation somatostatin analog (SSA) long acting pasireotide (la-PAS) has recently been introduced for the management of patients uncontrolled by first-generation SSA. The ACRONIS study (CSOM230CIC05) will provide real-wo...

ea0056p977 | Paediatric endocrinology | ECE2018

Association of placental thyroid hormone concentrations with congenital cryptorchidism

Li Zhong-Min , Hernandez-Moreno David , Main Katharina Maria , Skakkebaek Niels Erik , Kiviranta Hannu , Toppari Jorma , Feldt-Rasmussen Ulla , Shen Heqing , Schramm Karl-Werner , De Angelis Meri

The placenta is a highly specialized organ, which ensures nutrient uptake, waste elimination, provides thermo-regulation, prevents passage of some xenobiotic molecules and regulates the quantity of thyroid hormones (TH) necessary for the fetal development. It is known, that even minor changes in maternal TH levels, can alter the fetal growth. Several factors can modify TH levels during pregnancy. Among them, increasing evidences show that prenatal exposure to persistent organi...

ea0056p1008 | Endocrine Disruptors | ECE2018

A validated LC-Q-TOF-MS method for quantitative analysis of thyroxine and metabolites in placenta

Li Zhong-Min , Giesert Florian , Vogt-Weisenhorn Daniela , Main Katharina , Skakkebaek Niels , Kiviranta Hannu , Toppari Jorma , Feldt-Rasmussen Ulla , Shen Heqing , Schramm Karl-Werner , Angelis Meri De

Thyroid hormones (TH) of maternal origin are critical for the proper fetal development, especially during early pregnancy. Even minor changes in maternal TH circulation can lead to various adverse outcomes. Recent studies found that the metabolites of thyroxine (T4) also play an important physiological role. For example, 3,5-diiodo-L-thyronine (T2) and 3,3′-diiodo-L-thyronine (rT2) can suppress the thyroid stimulating hormone (TSH) level ...

ea0099oc1.3 | Oral Communications 1: Reproductive and Developmental Endocrinology | ECE2024

Pregnancy loss in women with endocrine disorders – a nationwide registry-based cohort study of 366,548 Danish women

Egerup Pia , Bliddal Sofie , Westergaard David , Glintborg Dorte , Bonnema Steen J. , Feldt-Rasmussen Ulla , Nyegaard Mette , Mortensen Laust Hvas , Svarre Nielsen Henriette

Background: Pregnancy loss affects approximately 25% of pregnancies, of which 40% have no detectable chromosome abnormalities and are suspected to be caused by maternal comorbidity. Pregnancy loss has been associated with specific endocrine disorders, e.g. autoimmune thyroid disease (AITD), polycystic ovarian syndrome (PCOS) or diabetes mellitus (DM). Because of the well-described overlap between these endocrine disorders, we hypothesized that pregnancy loss is associated with...

ea0081p517 | Adrenal and Cardiovascular Endocrinology | ECE2022

Impact of glucocorticoid-induced adrenal insufficiency on health-related quality of life

Willemoes Borresen Stina , Brun Boesen Victor , Watt Torquil , Bue Bjorner Jakob , Baslund Bo , Locht Henning , Bjork Thorgrimsen Toke , Jensen Bente , Sorensen Soren Schwartz , Lund Hetland Merete , Hansen Annette , Norregaard Jesper , Klose Marianne , Feldt-Rasmussen Ulla

Objective: Glucocorticoid-induced adrenal insufficiency is highly prevalent, but the clinical consequences are not fully understood. Therefore, the indication of adding stress dosages of glucocorticoid during ongoing anti-inflammatory glucocorticoid treatment remains unclear. The aim of this study was to determine the impact of adrenal function on health-related quality of life (HRQoL) in patients receiving ongoing low-dose prednisolone treatment.Methods...